Lauren Mason, PA
Surgical · Baltimore, MDNPI 1437873189
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 35 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Revance Therapeutics, Inc. accounts for 81.7% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $1,276, more than ten times the $25 reported in 2023.
Across 35 payments — averaging $49.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Revance Therapeutics, Inc.$1K
- Galderma Laboratories, L.p.$172
- Stryker$46
- BD$36
- C. R. Bard, Inc. & Subsidiaries$25
- Medacta USA, Inc.$21
- plus $16 from 1 others
What the payments were for
- Food & beverage$1,732100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Revance Therapeutics, Inc. | 25 | $1,416 |
| Galderma Laboratories, L.p. | 3 | $172 |
| Stryker | 3 | $46 |
| BD | 1 | $36 |
| C. R. Bard, Inc. & Subsidiaries | 1 | $25 |
| Medacta USA, Inc. | 1 | $21 |
| AbbVie | 1 | $16 |
How this compares
$1,732 in reported general payments places this provider in the 85th percentile of 277 surgical providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 12 | $8,054 |
| Meloxicam | 31 | $236 |
| Amoxicillin | 31 | $171 |
| Methylprednisolone | 24 | $168 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 16 | $156 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 28 | $124 |
| Cephalexin | 14 | $106 |
| Oxycodone Hcl | 17 | $95 |
| Cyclobenzaprine Hcl | 17 | $89 |
| Tramadol Hcl | 13 | $37 |
| Clindamycin Hcl | 11 | $24 |
Paid to pharmacies, not to this prescriber.
Other surgical in Baltimore
- Erika NigamBaltimore$8K
- Tara MorrisBaltimore$7K
- Simone BeattieBaltimore$7K
- Cairo KeenanBaltimore$4K
- Rakhmin KhoshayevBaltimore$4K
- Olga Duclos-LasnierBaltimore$4K
- Rashel CastelgrandeBaltimore$3K
- Samantha HammockBaltimore$2K
- Nam PhamBaltimore$2K
- Lindsey ManosBaltimore$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.